Catalogue of mutations in *Mycobacterium tuberculosis* complex and their association with drug resistance



Catalogue of mutations in *Mycobacterium tuberculosis* complex and their association with drug resistance



Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance

ISBN 978-92-4-002817-3 (electronic version) ISBN 978-92-4-002818-0 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Suggested citation. Catalogue of mutations in *Mycobacterium tuberculosis* complex and their association with drug resistance. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Contents

Acknowledgements	v
Abbreviations and acronyms	vii
Introduction	1
Development of the mutation catalogue	
Overview of the mutation catalogue	
Geographical distribution of data	5
Summary of phenotypic DST data	
Performance of confidence-graded mutations for predicting phenotypic drug susceptibility	7
Mutation catalogue	
Reading the tables	
An illustrative example	
Rifampicin	15
Isoniazid	
Ethambutol	
Pyrazinamide	
Levofloxacin and moxifloxacin	
Bedaquiline and clofazimine	
Linezolid	41
Delamanid	
Amikacin	
Streptomycin	
Ethionamide	48



Future research priorities	
Detailed methods	
Overview	
Data sources	
Curation of phenotypic DST data	
Prioritization of phenotypic DST results	
Variant analysis	
Annotation of variants	61
Association studies	61
Confidence grading	
Data contributors	
References	

Acknowledgements

Development of this document was led by Nazir Ahmed Ismail, Carl-Michael Nathanson and Alexei Korobitsyn, with support from Matteo Zignol and under the overall direction of Tereza Kasaeva, Director of the WHO Global TB Programme. The document is based on systematic analysis of a large collection of isolates of Mycobacterium tuberculosis complex with whole-genome sequencing and phenotypic drug-susceptibility testing. Data analysis, development of the catalogue and preparation of the report were conducted by four people, Timothy Rodwell, Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland and University of California, San Diego, USA; Paolo Miotto, San Raffaele Scientific Institute, Milan, Italy; Claudio Köser, University of Cambridge, United Kingdom; Timothy Walker, Oxford University, United Kingdom. Further support was provided by: Philip Fowler, Oxford University, United Kingdom; Jeff Knaggs, Oxford University, United Kingdom; Zamin Igbal, European Bioinformatics Institute, London, United Kingdom; Martin Hunt European Bioinformatics Institute, London, United Kingdom; Leonid Chindelevitch, Imperial College, London, United Kingdom; Maha Farhat, Harvard Medical School, Boston (MA), USA; Daniela Cirillo, San Raffaele Scientific Institute, Milan, Italy; Derrick Crook, Oxford University, United Kingdom; Iñaki Comas, Biomedicine Institute of Valencia, Spain; Jamie Posey, Centers for Disease Control and Prevention, Atlanta (GA), USA; Shaheed Vally Omar, National Institute for Communicable Diseases, Pretoria, South Africa; Tim Peto, Oxford University, United Kingdom; Sarah Walker, Oxford University, United Kingdom. Reviewing and editing of drafts was provided by Anita Suresh, Swapna Uplekar, Sacha Laurent and Rebecca Colman, FIND, Geneva, Switzerland. This work was funded by grants provided by Unitaid and the United States Agency for International Development.

WHO is grateful to the following people who provided technical input:

Heidi Albert, FIND, Cape Town, South Africa; Emmanuel André, University Hospitals Leuven, Belgium; Arnold Bainomugisa, Queensland Department of Health, Brisbane, Australia; Marie Ballif, University of Bern, Switzerland; Ivan Barilar, Forschungszentrum Borstel, Germany; Draurio Barreira Cravo Neto, Unitaid, Geneva, Switzerland; Alain Baulard, Institut Pasteur de Lille, France; Erik Böttger, University of Zürich, Switzerland; Francesc Coll, London School of Hygiene & Tropical Medicine, London, United Kingdom; Teresa Cortes, London School of Hygiene and Tropical Medicines, United Kingdom; Chris Coulter, Queensland Department of Health, Brisbane, Australia; Alan Cristoffels, University of the Western Cape, Bellville, South Africa; James Dawson, Centers for Disease Control and Prevention, Atlanta (GA), USA; Matthias Egger, University of Bern, Switzerland; Victoria Furió, Universitat de València, Spain; Sebastien Gagneux, Swiss Tropical and Public Health Institute, Basel, Switzerland; Wayne van Gemert, Stop TB Partnership, Geneva, Switzerland; Patricia Hall, Centers for Disease Control and Prevention, Atlanta (GA), USA; Zahra Hasan, The Aga Khan University, Karachi, Pakistan; Harald Hoffmann, Institute of Microbiology and Laboratory Medicine, Gauting, Germany; Babak Javid, University of California, San Francisco (CA), USA; Moses Joloba, National Reference Laboratory of the National TB and Leprosy Programme, Kampala, Uganda; George Kasule, National Reference Laboratory of the National TB and Leprosy Programme, Kampala, Uganda; Peter Keller, University of Bern, Switzerland; Ellis Kelly, University of Cambridge, United Kingdom; Marguerite Massinga Loembé, Africa CDC, Libreville, Gabon; Alberto Mendoza, Ministry of Health, Lima, Peru; Matthias Merker, Forschungszentrum Borstel, Germany; John Metcalf, University of California San Francisco (CA), USA; Satoshi Mitarai, Research Institute of Tuberculosis, Tokyo, Japan; Stefan Niemann, Forschungszentrum Borstel, Germany; Sushil Pandey, Queensland Department of Health, Brisbane, Australia; Amy Piatek, US Agency for International Development (USAID), Washington DC, USA; Paola Rancoita, Vita-Salute San Raffaele University, Milan, Italy; Leen Rigouts, Institute of Tropical Medicine, Antwerp, Belgium; Jaime Robledo, Corporación Para Investigaciones Biológicas, Medellín, Colombia; Camilla Rodrigues, P.D. Hinduja National Hospital and Medical Research Centre, Mumbai, India; Michael Whitfield, Institute of Tropical Medicine, Antwerp, Belgium; Zhao Yanlin, National Tuberculosis Reference Laboratory, China CDC, Beijing, China; Danila Zimenkov, Engelhardt Institute of Molecular Biology, Moscow, Russian Federation. Technical editing by Elisabeth Heseltine and design by Inis Communication.

预览已结束, 完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5 23765